The Thread of Life: Meet Klotho, the Longevity Protein

Abstract

In Greek mythology, Clotho was the youngest of the three Fates — the one who spun the thread of life. Your body carries a protein named in her honor. And like the thread she held, it determines far more about how you age than most people realize.

Klotho is not a supplement you can find at a pharmacy. It is not a vitamin, not a herbal extract, not something you can simply add to a shopping cart. Klotho is a protein your body produces naturally — primarily in the kidneys and the choroid plexus of the brain — and its levels follow a predictable arc: they peak in childhood, plateau in early adulthood, and begin a steady decline from your 30s onward. By the time most people reach 70, they are carrying roughly half the Klotho they had at 20.

Scientists have known about Klotho since 1997, when Japanese researcher Dr. Makoto Kuro-o discovered that mice lacking the gene encoding this protein aged dramatically and died young — while mice engineered to overproduce it lived 20 to 30 percent longer than normal and remained biologically younger across every organ system measured. That discovery set off decades of research that has only accelerated. In 2025 and 2026 alone, new publications confirmed what earlier animal studies suggested: in humans, higher circulating Klotho correlates with lower all-cause mortality, better cognitive function, preserved kidney health, cardiovascular resilience, and a measurably younger biological age.

There is now even a dedicated annual Klotho Conference — a gathering of the world’s leading researchers working to understand and harness this protein. The field has moved decisively from curiosity to organized clinical development.

This article is an introduction to Klotho — what it is, what it does, why its decline matters, and why it is becoming one of the most important conversations in longevity medicine.

What Klotho Actually Does

What makes Klotho remarkable — and what has kept longevity researchers focused on it for nearly three decades — is not that it does one spectacular thing. It is that it does many things at once, across multiple organ systems, addressing several of the fundamental drivers of biological aging simultaneously.

Anti-Inflammatory Signaling

Chronic, low-grade inflammation — what researchers call “inflammaging” — is now understood to be one of the central mechanisms driving age-related disease. Klotho modulates NF-κB signaling, the master switch of inflammatory response, dialing down the systemic background inflammation that accumulates with age and underlies cardiovascular disease, neurodegeneration, and metabolic dysfunction.

Antioxidant Defense

Klotho upregulates the body’s own endogenous antioxidant enzymes — particularly superoxide dismutase and catalase — reducing the oxidative damage that accumulates in cells over time and drives cellular senescence. This is not supplementing antioxidants from outside; it is restoring the body’s capacity to protect itself.

Brain and Cognitive Function

Klotho in the cerebrospinal fluid supports synaptic plasticity — the brain’s ability to form and maintain neural connections — and amplifies BDNF signaling in the hippocampus, the region most critical to memory and learning. In 2023, a single injection of Klotho protein enhanced memory in aged primates. The KL-VS genetic variant, which naturally boosts Klotho levels and is present in roughly one in four people, has been shown to reduce Alzheimer’s risk — even among carriers of the high-risk APOE ε4 allele.

Cardiovascular and Vascular Health

Klotho preserves endothelial function and prevents arterial stiffness. Through its partnership with FGF23, it also maintains phosphate balance — excess phosphate accelerates vascular calcification, one of the major drivers of cardiovascular mortality. Klotho keeps this in check.

Kidney Function

The kidneys are the primary site of Klotho production, and the relationship is bidirectional: Klotho supports kidney health, and kidney health supports Klotho. Chronic kidney disease accelerates Klotho decline — which in turn accelerates systemic aging. Restoring Klotho levels has shown measurable benefits for kidney function, including documented improvements in eGFR in clinical settings.

Muscle and Bone

A 2025 landmark study published in Molecular Therapy by researchers at the Universitat Autònoma de Barcelona confirmed that increasing levels of secreted Klotho (s-KL) in wild-type mice enhanced longevity, physical well-being, and neurological resilience — including preserved muscle mass and bone integrity. The research group subsequently filed three new patents protecting the use of Klotho for treating bone and muscle deficits and for therapies aimed at increasing longevity.

The Decline Curve — And Why It Matters

Klotho levels are not static. They follow a biological arc that is closely tied to chronological age — and accelerated by a number of lifestyle and health factors that are increasingly common in modern life.

The decline begins in your early 30s and is gradual at first. By age 50, most people have noticeably lower levels. By 70, the average person is operating at roughly half their youthful Klotho capacity. This decline runs in parallel with — and may partially drive — the cluster of changes we associate with aging: arterial stiffening, cognitive slowing, reduced kidney filtration, increased inflammation, and declining physical resilience.

What makes this particularly relevant is that the decline is not purely genetic. Chronic kidney disease significantly accelerates Klotho loss. So does chronic stress, sleep deprivation, sedentary behavior, high dietary phosphate, and metabolic dysfunction. This means that for many people, their Klotho levels are lower than they should be for their age — not simply because of birthdays, but because of the accumulated burden of modern life.

“Can’t You Just Take Klotho as a Supplement?”

This is the question longevity enthusiasts most commonly arrive at. And the honest answer is: not in any meaningful way, yet.

Klotho is a protein, not a small molecule. It cannot be effectively delivered as an oral supplement — the digestive system breaks it down before it can reach the bloodstream. Injectable Klotho protein formulations are being developed by several biotechnology companies, including Jocasta Neuroscience, which raised $35 million in 2025 to advance its proprietary subcutaneous Klotho protein therapeutic. But these remain in early clinical development, not yet available to patients.

Lifestyle interventions — regular aerobic exercise, quality sleep, dietary phosphate reduction, stress management, and adequate vitamin D — can support Klotho production and partially slow its decline. For people with relatively healthy baselines, these are meaningful interventions. But they cannot restore levels that have already substantially declined. They work within the range of what the body is already producing; they cannot reset the trajectory.

This is the gap that advanced clinical approaches are designed to address.

The Next Frontier: Restoring Klotho From Within

The most scientifically promising approach to meaningfully increasing Klotho levels is not delivering the protein from outside — it is instructing the body’s own cells to produce more of it from within. This is the logic of gene therapy.

Rather than injecting a protein that will be metabolized and cleared within hours, a gene therapy approach delivers the genetic instructions for Klotho production directly to cells. The cells then express the Klotho protein continuously, maintaining elevated circulating levels over an extended period. The effect is not a spike followed by a crash — it is a sustained restoration of the body’s own production capacity.

This approach offers something that no supplement, protein injection, or lifestyle modification can match: duration and physiological authenticity. The Klotho produced is the body’s own, expressed through its own cells, circulating as it naturally would — not as an introduced foreign molecule fighting clearance mechanisms.

When this kind of sustained Klotho restoration is combined with pluripotent stem cell (PSC) therapies and PSC-derived exosomes — each operating through distinct but complementary mechanisms — the synergistic effect on cellular repair, anti-senescence, and systemic regeneration goes well beyond what any single agent achieves alone. PSCs address structural and paracrine regenerative signaling; their exosomes carry adaptive, contextually responsive cargo; and sustained Klotho provides the hormonal anti-aging environment in which those regenerative processes can operate most effectively.

The combination is not additive. It is multiplicative.

A Protein Worth Knowing

Klotho was named for the goddess who held the thread of life. The science suggests the name was apt: few molecules have emerged as more central to the biology of how we age, across how many systems, at once.

Most people have never heard of it. That is beginning to change. The longevity biotech market is now directing billions of dollars toward Klotho-related programs. A dedicated annual Klotho Conference is drawing the field’s top researchers. And quietly, in clinical settings outside the United States, patients are already accessing approaches that go well beyond what conventional medicine currently offers.

The question worth asking is not whether Klotho matters — the science is clear on that. The question is: what is your level, and what can be done about it?

If that question interests you, we are here to discuss it.